Testing for Blastomycosis, Coccidioidomycosis, and Histoplasmosis at a Major Commercial Laboratory, United States, 2019–2024
Open Forum Infectious Diseases · 30.07.2024 · 11 (8)
DOI: 10.1093/ofid/ofae448 ↗Kurz gefasst
Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 02.08.2024. Verfasst von Kaitlin Benedict und 5 weiteren Autor:innen. Beteiligte Einrichtung: Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Blastomycosis, coccidioidomycosis, and histoplasmosis are environmentally acquired fungal diseases that clinically resemble bacterial and viral community-acquired pneumonia and require laboratory testing for diagnosis. Patients frequently present to primary care and experience diagnostic delays when a fungal etiology is not initially suspected. Current national-level public health surveillance for these diseases is limited and does not include laboratory data, so nationwide testing practices are unknown.
Methods
We identified laboratory tests for blastomycosis, coccidioidomycosis, and histoplasmosis ordered during 1 March 2019–29 February 2024 and performed within a major national commercial laboratory system. We analyzed test results, patient and healthcare provider features, reasons for testing, and temporal trends.
Results
Results included 5693 Blastomyces complement fixation tests (of those, 12% were positive), 71 858 immunodiffusion tests (0.1% positive), and 1186 serum enzyme immunoassay (EIA) tests (11% positive); 154 989 Coccidioides EIA immunoglobulin M results (5% positive) and 154 968 immunoglobulin G results (8% positive); and 46 346 Histoplasma complement fixation tests (30% positive), 49 062 immunodiffusion tests (1% positive), 35 506 serum EIA tests (4% positive), and 82 489 urine EIA tests (2% positive). Most histoplasmosis (58%–74%) and blastomycosis (42%–68%) tests were ordered from hospitals, whereas coccidioidomycosis tests were most frequently ordered by primary care providers (40%). A yearly average of 2727 positive tests were ordered by healthcare providers in states without public health surveillance for these diseases.
Conclusions
Blastomycosis, coccidioidomycosis, and histoplasmosis are likely underdetected in primary care settings or by public health surveillance. Increased testing by primary care providers and expanded surveillance are needed to reduce disease burden.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
ORCID-Profile: Kaitlin Benedict, Mitsuru Toda
Zitieren
APA
Benedict, K., Williams, S. L., Smith, D. J., Lindsley, M. D., Lockhart, S. R., & Toda, M. (2024). Testing for Blastomycosis, Coccidioidomycosis, and Histoplasmosis at a Major Commercial Laboratory, United States, 2019–2024. Open Forum Infectious Diseases, 11(8). https://doi.org/10.1093/ofid/ofae448
Vancouver
Benedict K, Williams SL, Smith DJ, Lindsley MD, Lockhart SR, Toda M. Testing for Blastomycosis, Coccidioidomycosis, and Histoplasmosis at a Major Commercial Laboratory, United States, 2019–2024. Open Forum Infectious Diseases. 2024;11(8). doi:10.1093/ofid/ofae448
BibTeX
@article{Benedict2024,
author = {Benedict, Kaitlin and Williams, Samantha L and Smith, Dallas J and Lindsley, Mark D and Lockhart, Shawn R and Toda, Mitsuru},
title = {Testing for Blastomycosis, Coccidioidomycosis, and Histoplasmosis at a Major Commercial Laboratory, United States, 2019–2024},
journal = {Open Forum Infectious Diseases},
year = {2024},
volume = {11},
number = {8},
doi = {10.1093/ofid/ofae448}
}
EUVIMED